Apramycin

Apramycin
Systematic (IUPAC) name
(2R,3R,4R,5S,6R)-5-amino-2- [((1R,2R,3R,4R,6R,8R)-8-amino-9- [(1R,2S,3R,4R,6R)-4,6-diamino-2,3- dihydroxy-cyclohexyl]oxy-2-hydroxy- 3-methylamino-5,10- dioxabicyclo[4.4.0]dec-4-yl)oxy]-6- (hydroxymethyl)oxane-3,4-diol
Clinical data
AHFS/Drugs.com International Drug Names
Identifiers
37321-09-8 
QA07AA92 QJ01GB90 QJ51GB90
PubChem CID 3081545
DrugBank DB04626 Yes
ChemSpider 2339128 Yes
UNII 388K3TR36Z Yes
KEGG D02322 Yes
ChEBI CHEBI:2790 Yes
ChEMBL CHEMBL1230961 
Chemical data
Formula C21H41N5O11
539.58 g/mol
  (what is this?)  (verify)

Apramycin (also Nebramycin II) is an aminoglycoside antibiotic used in veterinary medicine. It is produced by Streptomyces tenebrarius.[1]

Pharmacology

Indication

Apramycin is used for the treatment of bacterial infections in animals.

Mechanism of action

Apramycin stands out among aminoglycosides for its mechanism of action which is based on blocking translocation and its ability to bind also to the eukaryotic decoding site despite differences in key residues required for apramycin recognition by the bacterial target. The drug binds in the deep groove of the RNA which forms a continuously stacked helix comprising non-canonical C.A and G.A base pairs and a bulged-out adenine. The binding mode of apramycin at the human decoding-site RNA is distinct from aminoglycoside recognition of the bacterial target, suggesting a molecular basis for the actions of apramycin in eukaryotes and bacteria.

Spectrum of bacterial susceptibility and resistance

Apramycin can be used to treat bacterial infections in animals caused by Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The following shows susceptibility data on medically significant organisms:

[2]

References

  1. Ryden, R; Moore (1977). "BJ". J Antimicrob Chemother 3 (6): 609–613. doi:10.1093/jac/3.6.609. PMID 340441.
  2. http://antibiotics.toku-e.com/antimicrobial_1728.html